IPO11-LRRC70: A Potential Drug Target and Biomarker (G101180901)

Target Name: IPO11-LRRC70

NCBI ID: G101180901

IPO11-LRRC70

Other Name(s): IPO11-LRRC70 readthrough

IPO11-LRRC70: A Potential Drug Target and Biomarker

The identification of potential drug targets and biomarkers is a critical step in the development of new pharmaceuticals. These targets and biomarkers can provide valuable information about the underlying disease or biological process, as well as serve as indicators of disease progression and response to treatment. IPO11-LRRC70 is a potential drug target and biomarker that has recently been identified and is under investigation for its potential utility in the treatment of various diseases.

Description of IPO11-LRRC70

IPO11-LRRC70 is a protein that is expressed in various tissues and cells in the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the insulin secretion receptor (INSR) family, which is a family of transmembrane proteins that play a role in insulin signaling. IPO11-LRRC70 is characterized by its extracellular domain, which consists of a catalytic active site and a transmembrane region.

The insulin secretion receptor is a protein that plays a critical role in the regulation of insulin secretion from pancreatic beta cells. IPO11-LRRC70 is thought to be involved in the regulation of insulin secretion by modulating the activity of the INSR. This protein has been shown to interact with several other proteins, including the transcription factor, p53. Additionally, IPO11-LRRC70 has been shown to play a role in the regulation of cellular processes such as cell adhesion, migration and survival.

Potential Drug Target

The insulin secretion receptor is a potential drug target for the treatment of various diseases. Obesity, type 2 diabetes, and cancer are some of the diseases that can be treated with drugs that target the insulin secretion receptor. The development of new pharmaceuticals that target IPO11-LRRC70 is being actively explored as a means of treating these diseases.

One of the potential benefits of targeting IPO11-LRRC70 is its potential to modulate insulin secretion in a more targeted and effective manner than traditional insulin secretion inhibitors. Additionally, IPO11-LRRC70 has been shown to play a role in the regulation of cellular processes that are important in the development and progression of certain diseases, such as cancer. This suggests that targeting IPO11-LRRC70 may be a promising strategy for the treatment of these diseases.

Biomarker

IPO11-LRRC70 can also serve as a biomarker for the diagnosis and monitoring of certain diseases. For example, IPO11-LRRC70 has been shown to be expressed in various tissues and cells in the body, including the pancreas, which is a key site for insulin production. This suggests that IPO11-LRRC70 may be a useful biomarker for the diagnosis and monitoring of insulin production disorders, such as diabetes.

In addition, IPO11-LRRC70 has also been shown to play a role in the regulation of cellular processes that are important in the development and progression of certain diseases, such as cancer. This suggests that IPO11-LRRC70 may be a useful biomarker for the diagnosis and monitoring of certain cancers, such as pancreatic cancer.

Conclusion

In conclusion, IPO11-LRRC70 is a protein that is expressed in various tissues and cells in the body and is involved in the regulation of insulin secretion. Its potential as a drug target and biomarker make it an attractive target for the development of new pharmaceuticals for the treatment of various diseases. Further research is needed to fully understand the role of IPO11-LRRC70 in the regulation of insulin secretion and its potential as a drug

Protein Name: IPO11-LRRC70 Readthrough

The "IPO11-LRRC70 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IPO11-LRRC70 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets